Contract Notice: Open House Original Discount Contracts 2023-02 - Lamivudin/Abacavir/Dolutegravir (Active Ingredient Combination) Pharmaceutical Products Short Description: The Health Insurance Companies Involved Pursue The Goal Of Concluding Discount Contracts According To 130C Sgb V With All Suitable Pharmaceutical Entrepreneurs To The Active Ingredient Lamivudin/Abacavir/Dolutegravir (Combination Of Active Ingredients). The Contract Is Concluded As Part Of The Open-House House Of Health Insurance Companies: Individual Negotiations On Contract Content Are Not Conducted, Uniform Conditions Apply. The Health Insurance Companies Do Not Allow Individual Contractual Partners To Have Exclusivity. The Contract Term Is A Maximum Of 24 Months Starting On 01.03.2023. The Contract Ends At The Latest On February 28, 2025, Regardless Of The Date Of The Conclusion Of The Contract. In The Event Of A Patent Before 28.02.2025, The Contract Automatically Ends With The End Of The Month Of The Patent. All Further Information Can Be Found In The Participation And Contract Documents. Deadline For Submission: 20250228 23:58 Type Of Buyer: Body Governed By Public Law Type Of Contract: Supplies Type Of Procedure: Open Procedure Regulation: European Union, With Participation By Gpa Countries Type Of Bid: Submission For All Lots Award Criteria: The Most Economic Tender [Disclaimer: The Above Text Is Machine Translated. For Accurate Information Kindly Refer The Original Document.] Tender Link : Https://Ted.Europa.Eu/Udl?Uri=Ted:Notice:022458-2023:Data:En:Html
Dear Sir,
Warm Greetings from TenderDetail.com !!
We have received Tender Document request for the TDR No : 59384175
Tender Notice along with it's Attachments ( Tender Document / Scan Image of News Paper)
sent to your Email Address :.
Please check your email for Tender Document.
